Fry Laboratories, LLC - Result Report 15720 N. Greenway-Hayden Loop Suite 3 Scottsdale, Az 85260 LABORATORIES, L.L.C

CLIA#03D1026968 info@frylabs.com 866.927.8075(p) 480.656.4932(f) 480.292.8457(billing)

WWW.FRYLABS.COM

Patient: Patient #: Doctor:

Maidenberg, Ryan

43738

Winstrom, Margit

Birth: Age:

Gender:

1/23/1990

25 years

Male

Acc #:

22641

Collection Date: Received in Lab: 12/10/2015 3:00 PM 12/11/2015 10:44 AM

DM

Test Name

Result

Units


Flag

Reference Range

Advanced Stains

Run by: DM on 12/11/2015 11:46 AM

Fluorescent & Enrichment Stains (Advanced Stain Test)



Notes: DETECTED (FEW) - Few biofilm community-like structures, neutrophil extracellular traps, and/or organisms were observed using a fluorescent DNA staining technology (1-8) or Giemsa using enrichment via centrifugation (9, 10). These findings are suggestive of an unspecified infectious and/or parasitic disease. The magnification is listed on the image above. References: (1)An alternative interpretation of nanobacteria-induced biomineralization. PNAS, 2000 Aug; 97 (21):11511-15 Cisar JO, et al. (2)Biofilm Formation by Pneumocystis spp. Eukary Cell, 2009 Feb; 8 (2):197-206 Cushion MT, et al. (3)Evolving concepts in biofilm infections. Cell Microbio, 2009 Apr; Microreview, Hall-Stoodley L, Stoodley P. (4)Evidence of nanobacterial-like structures in calcified human ateries and cardiac valves. Am J Physiol Heart Circ Physiol, 2004 May; 287:H1115-24 Miller VM, et al. (5)A Stochastic Mechanism for Biofilm Formation by Mycoplasma pulmonis. J of Bacteriol, 2007 Mar; 189 (5):1905-13 Simmons WL, et al. (6)Molecular and Imaging Techniques for Bacterial Biofilms in Joint Arthroplasty Infections, Clin Ortho and Rel Res, 2005 437: 31-40 Stoodley PS, et al. (7)Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. PNAS, 2009 Apr; 106(16):6748-53 Guimaraes-Costa AB, et al. (8)Biofilm Formation by the Fungal Pathogen Candida albicans: Development, Architecture, and Drug Resistance. J of Bacteriol, 2001 Sept; 183(18):5385-94 Chandra J, et al. (9)Differential Centrifugation and Infectivity of Babesia rodhaini Freed by Continuous-Flow Ultrasonication. J of Parasitol, 1978 Jun; 64 (3):554-6 Abdalla HS, et al. (10)Continuous in vitro propagation of the malaria parasite Plasmodium vivax. PNAS, 1997 Jun; 94 (13):6786-91 Golenda CF, et al. Stain quality is verified by internal controls for each run and external controls for each stain batch. This test is not FDA approved and is for research or

Originally Reported On: 1/11/2016 7:39 AM

Printed: 1/11/2016 7:39 AM

Page 1 of 4

STAT[S] Corrected [C] Added [A]

22641

WWW.FRYLABS.COM

ABORATORIES, L.L.C

Patient #: 43738

Maidenberg, Ryan Winstrom, Margit

Birth: Age: Gender: 1/23/1990

Male

25 years

Collection Date: Received in Lab:

Acc #:

12/10/2015 3:00 PM

12/11/2015 10:44 AM

DM

Test Name

Patient:

Doctor:

Result

Units

Flag

Reference Range Run by: DM on 12/11/2015 11:46 AM


Advanced Stains

investigational use only. Patent Pending 2009. Fry Laboratories, LLC.

Special Stains

Special Stains (Stained Blood Film Test)

Run by: DM on 12/11/2015 12:55 PM



Notes: No organisms observed.

References: (1)Boulouis HJ, Gang C, Henn J, Kasten R, Chomel BB. Factors associated with the rapid emergence of zoonotic Bartonella infections. Vet. Res. 36(2005) pg383-410. Harrison's Principles of Internal Medicine 15th edition. 2001. Nelson RW, Couto CG. Small Animal Internal Medicine 3rd edition. pg1233. Tilley LP, Smith FWK. The 5-minute Veterinary Consult 2nd edition. Walker TS, Winkler HH. Bartonella baciliformis: Colonial Types and Erythrocyte Adherence. Infect immune. 1981 Jan; 31 (1):480-86. Williams and Wilkins 2001 pg750. (2)Outbreaks of Hemotrophic Mycoplasma Infections in China. Emerg Infect Dis. 2009 Jul. Hu Z, et al. Hemotrophic mycoplasmas (hemoplasmas): a review and new insights into pathogenic potential. Vet. Clin. Path. 33(2004) pg2-13 Messick JB. Mycoplasma ovis comb. Nov. (formerly Eperythrozoon ovis), an epierythrocytic agent of haemolytic anaemia in sheep and goats. Internat J. of Sys and Evol Microbio. 54(2004) pg365-71 Neimark H, et al. From Haemobartonella to hemoplasma: Molecular methods provide new insights. Vet. Microbio. 125(2007) pg197-209 Willi B, et al. (3)Molecular and enrichment studies by Fry Laboratories show that these organisms could be Protozoal, Phylum unknown. Stain quality is verified by internal controls for each run and external controls for each stain batch. This test is not FDA approved and is for research use only.

Originally Reported On:

1/11/2016 7:39 AM

Printed: 1/11/2016 7:39 AM

Page 2 of 4

STAT[S] Corrected [C] Added [A]



22641

WWW.FRYLABS.COM

Patient:

Maidenberg, Ryan

43738

Winstrom, Margit

Birth: Age: Gender: 1/23/1990

25 years Male Collection Date:

12/10/2015 3:00 PM

12/11/2015 10:44 AM

Test Name

Doctor:

Result

Units

Received in Lab:

Reference Range

DM

Run by: DSM on 12/22/2015 10:05 AM

Protomyxzoa (FL1953) PCR

ABNORMAL

Flag

Acc #:

Protomyxzoa (FL1953) by PCR

INDETERMINATE, PCR inhibitors present

Not Detected

DETECTED - DNA sequence specific for Protomyxzoa (FL1953) was found at detectable levels in the patient sample utilizing a PCR based assay. A "DETECTED" result should be considered in conjunction with clinical presentation and additional diagnostic tests prior to establishing a diagnosis.

NOT DETECTED - DNA sequence specific for Protomyxzoa (FL1953) was not found at detectable levels in the patient sample utilizing a PCR based assay. A "NOT DETECTED" result should be considered in conjunction with clinical presentation and additional diagnostic tests prior to establishing a diagnosis. The threshold of detection has not been established for this assay.

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test have been validated by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The current status of Protomyxzoa (FL1953) is undergoing scientific inquiry, therefore the causation/correlation with specific disease processes and treatment has yet to be determined fully. For additional information regarding Protomyxzoa (FL1953) research contact the laboratory. Patent Pending 2009, 2010, and 2011 Fry Laboratories, LLC.

Pan-Bacterial Metagenomics

Run by: DM on 12/15/2015 11:00 AM

Pan-Bacterial Metagenomics by Sequencing

SEE ATTACHED SEQUENCE REPORT

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test are still undergoing validation and verification by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Sequence results are considered proprietary and Fry Laboratories, LLC may retain patent rights. Patent Pending 2013 Fry Laboratories, LLC. Results are not representative of standard patient test results as it was performed as research. This assay was performed on an investigational and research basis and care should be taken when interpreting these results in combination with diagnostic tests.

Pan-Protozoal Metagenomics

Run by: DM on 1/6/2015 7:39 AM

Pan-Protozoal Metagenomics by Sequencing

SEE ATTACHED SEQUENCE REPORT

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test are still undergoing validation and verification by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Sequence results are considered proprietary and Fry Laboratories, LLC may retain patent rights. Patent Pending 2013 Fry Laboratories, LLC. Results are not representative of standard

Originally Reported On: 1/11/2016 7:39 AM

Printed: 1/11/2016 7:39 AM

Page 3 of 4

Accession: 22641 Patient ID: 43738 Lab Results For: Ryan Maidenberg

STAT[S] Corrected [C] Added [A]



WWW.FRYLABS.COM

Patient: Patient #: Maidenberg, Ryan

43738 Winstrom, Margit

Birth: Age:

Gender:

1/23/1990

25 years

Acc #:

22641

Collection Date: Received in Lab: 12/10/2015 3:00 PM

DM

Test Name

Doctor:

Result

Units

Male

12/11/2015 10:44 AM

Pan-Protozoal Metagenomics

Flag

Reference Range

Run by: DM on 1/6/2015 7:39 AM patient test results as it was performed as research. This assay was performed on an investigational and research basis and care should be taken when interpreting these results in

combination with diagnostic tests.

Reviewed by: Dr. Stephen E. Fry, M.S., M.D., Laboratory Director

Accession: 22641 Patient ID: 43738

Lab Results For: Ryan Maidenberg

WWW.FRYLABS.COM

TRT LABORATORIES, L.L.C.			
Patient: Maidenberg, Ryan	Sample #:	22641-12207	Sample Type: Blood
Doctor: Winstrom, Margit	Birth:	1/23/1990	Collection Date: 12/10/2015
Gender: Male	Prepared By:	DM	Completion Date: 12/16/2015

Pan-Bacterial Metagenomics

 NO SIGNIFICANT SEQUENCE RESULTS – No significant results were obtained that met internal quality standards. A "NO SIGNIFICANT SEQUENCE RESULTS" result should be considered in conjunction with clinical presentation and additional diagnostic tests prior to establishing a diagnosis.

Notes

Sequence Information: 57,085 sequence reads were obtained for the given sample. The longest 14,483 sequences were analyzed and compared to all available prokaryotic species. Results Confidence Profile: At the provided quality control cut-off it is estimated that >95% of the sequence reads correctly list the genus, while >30% of the sequence reads correctly list the species.

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test are still undergoing validation and verification by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The following genera have been reported as difficult to identify using 16S sequencing: Aeromonas, Bacillus, Bordetella, Burkholderia, Campylobacter, Edwardsiella, Enterobacter, Neisseria, Pseudomonas, and Streptococcus. Sequence results are considered proprietary and Fry Laboratories, LLC may retain patent rights. Patent Pending 2013 Fry Laboratories, LLC. This assay was performed on an investigational and research basis and care should be taken when interpreting these results in combination with diagnostic tests. Reviewed by S. Fry, M.D.



OF 20	oπsdaie, Az	85200		000.327.00	1/3(p) 480.030.4332(1) 4	80.232.8437(billing
RY LAB	ORATORIE	S, L.L.C.				WWW.FRYLABS.COM
atient:_Ma	aidenberg, Ry	/an	Sample #:	22641-12770	Sample Type:	Blood
octor: W	instrom, Mar	git	Birth:	1/23/1990	Collection Date:	12/10/2015
ender: Ma	ale		Prepared By:	DM/DSM	Completion Date:	1/06/2016
an-Protoz	oal Metagen	omics		- ····		
	70					
	60 -					
ion	50 -		-			
ibut	40 -		-	error democratic		
% Contribution	30					
°C	20			***************************************		
6	10		-			
	0	P	erkinsus species		Saccharomyces cere	evisiae
✓ Pote	ential Novel		0.07		0.04	
■ Clos	e Match		64.11	***************************************	21.46	
1						

Complete Significant Contribution

Species Name	Close Match	Potential Novel	Total Percent	Match Count	Novel Count	Total Count
Perkinsus species	64.11	0.07	64.18	2901	3	2904
Saccharomyces cerevisiae	21.46	0.04	21.5	971	2	973

Notes

Sequence Information: 47,231 sequence reads were obtained for the given sample. The longest 5,655 sequences were analyzed and compared to all available eukaryotic species. *: Multiple regions were sequenced for the organism counts indicated by an asterisk. Results Confidence Profile: At the provided quality control cut-off it is estimated that >95% of the sequence reads correctly list the genus, while >30% of the sequence reads correctly list the species.

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test are still undergoing validation and verification by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Phylogenetically the following genera likely should be considered same genus, but are not due to historical or medical terminology considerations and may therefore be cross genus identified: Escherichia and Shigella. Sequence results are considered proprietary and Fry Laboratories, LLC may retain patient rights. Patient Pending 2013 Fry Laboratories, LLC. Results are not representative of standard patient test results as it was performed as research. This assay was performed on an investigational and research basis and care should be taken when interpreting these results in combination with diagnostic tests. Reviewed by S. Fry, M.D.



22641

WWW.FRYLABS.COM

Patient: Patient #: Doctor:

Maidenberg, Ryan

43738

Winstrom, Margit

Birth: Age:

Gender:

1/23/1990

25 years

Male

Collection Date: Received in Lab:

Acc #:

12/10/2015 3:00 PM

DM 12/11/2015 10:44 AM

Test Name

Result

Units


Flag

Reference Range

Run by: DM on 12/11/2015 11:46 AM

Advanced Stains

Fluorescent & Enrichment Stains (Advanced Stain Test)



Notes: DETECTED (FEW) - Few biofilm community-like structures, neutrophil extracellular traps, and/or organisms were observed using a fluorescent DNA staining technology (1-8) or Giemsa using enrichment via centrifugation (9, 10). These findings are suggestive of an unspecified infectious and/or parasitic disease. The magnification is listed on the image above. References: (1)An alternative interpretation of nanobacteria-induced biomineralization. PNAS, 2000 Aug; 97 (21):11511-15 Cisar JO, et al. (2)Biofilm Formation by Pneumocystis spp. Eukary Cell, 2009 Feb; 8 (2):197-206 Cushion MT, et al. (3)Evolving concepts in biofilm infections. Cell Microbio, 2009 Apr. Microreview, Hall-Stoodley L, Stoodley P. (4)Evidence of nanobacterial-like structures in calcified human ateries and cardiac valves. Am J Physiol Heart Circ Physiol, 2004 May; 287:H1115-24 Miller VM, et al. (5)A Stochastic Mechanism for Biofilm Formation by Mycoplasma pulmonis. J of Bacteriol, 2007 Mar; 189 (5):1905-13 Simmons WL, et al. (6)Molecular and Imaging Techniques for Bacterial Biofilms in Joint Arthroplasty Infections. Clin Ortho and Rel Res, 2005 437: 31-40 Stoodley PS, et al. (7)Leishmania amazonensis promastigotes induce and are killed by neutrophil extracellular traps. PNAS, 2009 Apr; 106(16):6748-53 Guimaraes-Costa AB, et al. (8)Biofilm Formation by the Fungal Pathogen Candida albicans: Development, Architecture, and Drug Resistance. J of Bacteriol, 2001 Sept; 183(18):5385-94 Chandra J, et al. (9)Differential Centrifugation and Infectivity of Babesia rodhaini Freed by Continuous-Flow Ultrasonication. J of Parasitol, 1978 Jun; 64 (3):554-6 Abdalla HS, et al. (10)Continuous in vitro propagation of the malaria parasite Plasmodium vivax. PNAS, 1997 Jun; 94 (13):6786-91 Golenda CF, et al. Stain quality is verified by internal controls for each run and external controls for each stain batch. This test is not FDA approved and is for research or

Originally Reported On:

Page 1 of 4

1/11/2016 7:39 AM Printed: 1/11/2016 7:39 AM

Fry Laboratories, LLC - Result Report 15720 N. Greenway-Hayden Loop Suite 3 Scottsdale, Az 85260

CLIA#03D1026968 info@frylabs.com 866.927.8075(p) 480.656.4932(f) 480.292.8457(billing)

WWW.FRYLABS.COM

Patient: Patient #:

Doctor:

ABORATORIES, L.L.C Maidenberg, Ryan

43738

Winstrom, Margit

Birth: Age:

Gender:

1/23/1990

25 years

Male

Acc #:

22641

Collection Date: Received in Lab: 12/10/2015 3:00 PM

12/11/2015 10:44 AM

DM

Test Name

Result

Units

Flag

Reference Range

Run by: DM on 12/11/2015 11:46 AM


Advanced Stains

investigational use only. Patent Pending 2009. Fry Laboratories, LLC.

Special Stains

Special Stains (Stained Blood Film Test)

Run by: DM on 12/11/2015 12:55 PM



Notes: No organisms observed.

References: (1)Boulouis HJ, Gang C, Henn J, Kasten R, Chomel BB. Factors associated with the rapid emergence of zoonotic Bartonella infections. Vet. Res. 36(2005) pg383-410. Harrison's Principles of Internal Medicine 15th edition. 2001. Nelson RW, Couto CG. Small Animal Internal Medicine 3rd edition. pg1233. Tilley LP, Smith FWK. The 5-minute Veterinary Consult 2nd edition. Walker TS, Winkler HH. Bartonella baciliformis: Colonial Types and Erythrocyte Adherence. Infect immune. 1981 Jan; 31 (1):480-86. Williams and Wilkins 2001 pg750. (2)Outbreaks of Hemotrophic Mycoplasma Infections in China. Emerg Infect Dis. 2009 Jul. Hu Z, et al. Hemotrophic mycoplasmas (hemoplasmas): a review and new insights into pathogenic potential. Vet. Clin. Path. 33(2004) pg2-13 Messick JB. Mycoplasma ovis comb. Nov. (formerly Eperythrozoon ovis), an epierythrocytic agent of haemolytic anaemia in sheep and goats. Internat J. of Sys and Evol Microbio. 54(2004) pg365-71 Neimark H, et al. From Haemobartonella to hemoplasma: Molecular methods provide new insights. Vet. Microbio. 125(2007) pg197-209 Willi B, et al. (3)Molecular and enrichment studies by Fry Laboratories show that these organisms could be Protozoal, Phylum unknown. Stain quality is verified by internal controls for each run and external controls for each stain batch. This test is not FDA approved and is for research use only.

Originally Reported On:

1/11/2016 7:39 AM

Printed: 1/11/2016 7:39 AM

Page 2 of 4

STAT[S] Corrected [C] Added [A]



Result

CLIA#03D1026968 info@frylabs.com 866.927.8075(p) 480.656.4932(f) 480.292.8457(billing)

22641

WWW.FRYLABS.COM

LABORATORIES, L.L.C

43738 Patient #:

Patient:

Doctor:

Winstrom, Margit

Maidenberg, Ryan

Birth: Age:

Gender:

1/23/1990

25 years

Male

Collection Date:

Acc #:

Received in Lab:

12/10/2015 3:00 PM 12/11/2015 10:44 AM

DM

Test Name

Units

Reference Range Flag

Run by: DSM on 12/22/2015 10:05 AM

Protomyxzoa (FL1953) PCR

ABNORMAL

Protomyxzoa (FL1953) by PCR

INDETERMINATE, PCR inhibitors present

DETECTED - DNA sequence specific for Protomyxzoa (FL1953) was found at detectable levels in the patient sample utilizing a PCR based assay. A "DETECTED" result should be considered in conjunction with clinical presentation and additional diagnostic tests prior to establishing a diagnosis.

NOT DETECTED - DNA sequence specific for Protomyxzoa (FL1953) was not found at detectable levels in the patient sample utilizing a PCR based assay. A "NOT DETECTED" result should be considered in conjunction with clinical presentation and additional diagnostic tests prior to establishing a diagnosis. The threshold of detection has not been established for this assay.

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test have been validated by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The current status of Protomyxzoa (FL1953) is undergoing scientific inquiry, therefore the causation/correlation with specific disease processes and treatment has yet to be determined fully. For additional information regarding Protomyxzoa (FL1953) research contact the laboratory. Patent Pending 2009, 2010, and 2011 Fry Laboratories, LLC.

Pan-Bacterial Metagenomics

Run by: DM on 12/15/2015 11:00 AM

Pan-Bacterial Metagenomics by Sequencing

SEE ATTACHED SEOUENCE REPORT

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. performance characteristics of this test are still undergoing validation and verification by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Sequence results are considered proprietary and Fry Laboratories, LLC may retain patent rights. Patent Pending 2013 Fry Laboratories, LLC. Results are not representative of standard patient test results as it was performed as research. This assay was performed on an investigational and research basis and care should be taken when interpreting these results in combination with diagnostic tests.

Pan-Protozoal Metagenomics

Run by: DM on 1/6/2015 7:39 AM

Pan-Protozoal Metagenomics by Sequencing

SEE ATTACHED SEQUENCE REPORT

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test are still undergoing validation and verification by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Sequence results are considered proprietary and Fry Laboratories, LLC may retain patent rights. Patent Pending 2013 Fry Laboratories, LLC. Results are not representative of standard

Originally Reported On: 1/11/2016 7:39 AM

Printed: 1/11/2016 7:39 AM

Page 3 of 4

STAT[S] Corrected [C] Added [A]



22641

WWW.FRYLABS.COM

LABORATORIES, L.L.C

Patient: Maidenberg, Ryan Patient #:

43738

Winstrom, Margit

Birth: Age:

Gender:

1/23/1990

25 years

Collection Date:

Received in Lab:

Acc #:

12/10/2015 3:00 PM

12/11/2015 10:44 AM

DM

Test Name

Doctor:

Result

Male Units

Flag

Reference Range

Pan-Protozoal Metagenomics

Run by: DM on 1/6/2015 7:39 AM


patient test results as it was performed as research. This assay was performed on an investigational and research basis and care should be taken when interpreting these results in combination with diagnostic tests.

Reviewed by: Dr. Stephen E. Fry, M.S., M.D., Laboratory Director

Accession: 22641 Patient ID: 43738

Lab Results For: Ryan Maidenberg

FRY LABORATORIES, L.L.C.		AND REAL PROPERTY AND ADDRESS OF THE PARTY.		WWW.FREADS.COM
Patient: Maidenberg, Ryan	Sample #:	22641-12770	Sample Type:	Blood
Doctor: Winstrom, Margit	Birth:	1/23/1990	Collection Date:	12/10/2015
Gender: Male	Prepared By:	DM/DSM	Completion Date:	1/06/2016



Complete Significant Contribution

Species Name	Close Match	Potential Novel	Total Percent	Match Count	Novel Count	Total Count
Perkinsus species	64.11	0.07	64.18	2901	3	2904
Saccharomyces cerevisiae	21.46	0.04	21.5	971	2	973

Notes

Sequence Information: 47,231 sequence reads were obtained for the given sample. The longest 5,655 sequences were analyzed and compared to all available eukaryotic species. *: Multiple regions were sequenced for the organism counts indicated by an asterisk. Results Confidence Profile: At the provided quality control cut-off it is estimated that >95% of the sequence reads correctly list the genus, while >30% of the sequence reads correctly list the species.

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test are still undergoing validation and verification by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. Phylogenetically the following genera likely should be considered same genus, but are not due to historical or medical terminology considerations and may therefore be cross genus identified: Escherichia and Shigella. Sequence results are considered proprietary and Fry Laboratories, LLC may retain patient rights. Patient Pending 2013 Fry Laboratories, LLC. Results are not representative of standard patient test results as it was performed as research. This assay was performed on an investigational and research basis and care should be taken when interpreting these results in combination with diagnostic tests. Reviewed by S. Fry, M.D.

FRY LABORATORIES, L.L.C.		WWW.FRYLABS.COM		
Patient: Maidenberg, Ryan	Sample #:	22641-12207	Sample Type:	Blood
Doctor: Winstrom, Margit	Birth:	1/23/1990	Collection Date:	12/10/2015
Gender: Male	Prepared By:	DM	Completion Date	:12/16/2015

Pan-Bacterial Metagenomics

 NO SIGNIFICANT SEQUENCE RESULTS — No significant results were obtained that met internal quality standards. A "NO SIGNIFICANT SEQUENCE RESULTS" result should be considered in conjunction with clinical presentation and additional diagnostic tests prior to establishing a diagnosis.

Notes

Sequence Information: 57,085 sequence reads were obtained for the given sample. The longest 14,483 sequences were analyzed and compared to all available prokaryotic species. Results Confidence Profile: At the provided quality control cut-off it is estimated that >95% of the sequence reads correctly list the genus, while >30% of the sequence reads correctly list the species.

This test uses a kit/reagent designated by the manufacturer as for research use only, not for clinical use. Fry Laboratories, LLC developed this test or some of its components. The performance characteristics of this test are still undergoing validation and verification by Fry Laboratories, LLC. It has not been cleared or approved by the U.S. Food and Drug Administration. No international standard is currently available for the calibration of this assay. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. The following genera have been reported as difficult to identify using 16S sequencing: Aeromonas, Bacillus, Bordetella, Burkholderia, Campylobacter, Edwardsiella, Enterobacter, Neisseria, Pseudomonas, and Streptococcus. Sequence results are considered proprietary and Fry Laboratories, LLC may retain patent rights. Patent Pending 2013 Fry Laboratories, LLC. This assay was performed on an investigational and research basis and care should be taken when interpreting these results in combination with diagnostic tests. Reviewed by S. Fry, M.D.